Skip to content
Find My Test

Grail Galleri Multi-Cancer Test from Superpower

Labbrary Test GradeUseful
Your Fit Score
Not calculated

Answer five questions to see how this panel matches your goals, budget, collection preferences, access, and support needs.

Calculate my fit

Labbrary's review, Fit Score, and basic comparison are free. The provider's panel, shipping, collection, clinician review, and other services are separate. About 2 minutes. No account required.

Screens a blood sample for cancer-associated DNA methylation signals and, when a signal is detected, predicts a possible tissue of origin. Positive results require diagnostic follow-up; negative results do not rule out cancer or replace routine screening.

Current price
$949
Sample
Blood
Turnaround
14 to 21 days
Access
At Home, Mail In, Membership, Order Online
Evidence & Key Facts
Source collectedLast source check October 7, 2026

Sources. This grade is based on the seller pages listed on this page, as of the date shown.

Best for

Cancer Screening

Standout strength

One blood draw screens for signals associated with more than 50 cancer types in total and can provide a conditional Cancer Signal Origin prediction.

Important watch-out

Galleri is intended for adults at elevated cancer risk, such as people age 50 and older. It is not recommended during pregnancy, at age 21 or younger, or during active cancer treatment.

Grail Galleri Multi-Cancer Test from Superpower
Labbrary Test GradeUseful
Your Fit Score
Not calculated

Answer five questions to see how this panel matches your goals, budget, collection preferences, access, and support needs.

Calculate my fit

Labbrary's review, Fit Score, and basic comparison are free. The provider's panel, shipping, collection, clinician review, and other services are separate. About 2 minutes. No account required.

Screens a blood sample for cancer-associated DNA methylation signals and, when a signal is detected, predicts a possible tissue of origin. Positive results require diagnostic follow-up; negative results do not rule out cancer or replace routine screening.

Current price
$949
Sample
Blood
Turnaround
14 to 21 days
Access
At Home, Mail In, Membership, Order Online
Evidence & Key Facts
Source collectedLast source check October 7, 2026

Sources. This grade is based on the seller pages listed on this page, as of the date shown.

Best for

Cancer Screening

Standout strength

One blood draw screens for signals associated with more than 50 cancer types in total and can provide a conditional Cancer Signal Origin prediction.

Important watch-out

Galleri is intended for adults at elevated cancer risk, such as people age 50 and older. It is not recommended during pregnancy, at age 21 or younger, or during active cancer treatment.

Labbrary+

The Test Grade. The Reason Behind It.

Potentially useful for the right buyer, with meaningful evidence, coverage, transparency, access, cost, terms, or privacy tradeoffs to review.

A lower grade does not mean a panel is a bad personal fit. Your Fit Score can be higher when its purpose, price, sample, access, or support matches what you need.

Explore the Full Methodology
Labbrary Test GradeUseful

Next step

Review the panel or ask your clinician

This panel requires a licensed healthcare provider. Review the official details, then ask your clinician whether it is appropriate and how to order it.

Scope, both directions

Inside the Panel. Beyond the Name.

Named measurements

  • Cancer Signal Detected / No Cancer Signal Detected result (national and New York/New Jersey versions)
  • Cancer Signal Origin (CSO) prediction (national and New York/New Jersey versions)
  • Pancreatic cancer signal (national and New York/New Jersey versions)
  • Ovarian cancer signal (national and New York/New Jersey versions)
  • Liver and bile duct cancer signal (national and New York/New Jersey versions)
  • Esophageal cancer signal (national and New York/New Jersey versions)
  • Lung cancer signal (national and New York/New Jersey versions)
  • More than 50 cancer types screened in total (national and New York/New Jersey versions)

Measured categories and focus areas

  • Cancer Screening

Important limits and omissions

  • Superpower does not publish a complete named cancer-by-stage sensitivity inventory or patient-level report ranges.
  • Superpower does not publish outcome benefit data for routine use or the full cost of diagnostic follow-up.
  • Membership cancellation follows separate terms from the test.
  • Superpower does not publish GRAIL's specimen retention and destruction terms or exactly what data GRAIL exchanges with Superpower.

The full breakdown

Eight Dimensions.
One Named Result.

Open any row for the reasoning and evidence behind the named result.

The product page says a CAP-accredited laboratory operated by GRAIL runs this laboratory-developed test, validated under CLIA, which uses sequencing and machine learning to analyze methylation patterns; it is not cleared or approved by the FDA. The page does not publish assay precision data, reference-interval validation, or per-biomarker performance figures.

The product page describes this test for adults seeking multi-cancer early detection screening, and a prescription is required.

The product page screens for signals associated with more than 50 types of cancer and predicts the cancer signal origin. It does not publish a per-cancer list, so the inventory is described at the category level rather than as named analytes.

The product page says results are typically ready in about a week in the Superpower app, and that clinicians interpret them in context rather than as a stand-alone diagnosis. The page does not publish sample reports or reference intervals.

The product page names Superpower as the provider and a CAP-accredited laboratory operated by GRAIL as the lab, and gives the test's regulatory status. Corporate ownership, full terms of service, and lab credentials beyond the stated certification are not published on the page.

The product page states the test is available in 25 states, requires a prescription, and uses a single blood draw with results typically in two to three weeks. State-by-state availability beyond the 25-state figure is not published.

The product page lists the panel at $949 and says Superpower requires a $349 annual membership on top of the panel price. Refund and cancellation terms for the panel itself are not published on the page.

Superpower publishes a privacy policy covering the service, and the panel page notes results are delivered through the Superpower app. The panel page has no data-handling statement of its own, so it does not say how this panel's samples and data are stored, shared or deleted beyond the general policy.

What it asks of you

Sample and fulfillment journey

Order

Confirmed

Order through Superpower with a required prescription arranged through the order.

Seller page · Checked September 8, 2026

Collect

Confirmed

A licensed phlebotomist collects one blood sample at home. No fasting is required.

Seller page · Checked September 8, 2026

Lab

Confirmed

GRAIL analyzes DNA methylation patterns in the blood sample for cancer-associated signals. A detected signal can include a prediction of its tissue of origin.

Seller page · Checked September 8, 2026

Report

Confirmed

Receive results typically two to three weeks after collection. A detected signal requires diagnostic follow-up, and a no-signal result does not replace routine screening. Superpower's care-team support is non-clinical.

Seller page · Checked September 8, 2026

Under the hood

Follow the Evidence.

The seller pages behind this listing, with the date each was last checked.

Source 1Last checked October 7, 2026.View source
Source 2Last checked October 7, 2026.View source
Source 3Last checked October 7, 2026.View source
Source 4Last checked October 7, 2026.View source
Source 5Last checked October 7, 2026.View source

True total cost

The Price. Plus the Details.

Pricing for Grail Galleri Multi-Cancer Test
ItemCurrent disclosed priceNote
Panel$949Set by the ordering clinician or provider.
HSA/FSA paymentNot confirmedThe seller does not say whether this test is HSA/FSA eligible.
Optional servicesNot confirmedNo optional services are listed for this test.

Price status. No consumer price is published. Testing, collection, shipping and consultation fees depend on the ordering clinician or provider.

Your data

Your Data. Your Questions.

Superpower publishes a privacy policy covering the service, and the panel page notes results are delivered through the Superpower app. The panel page has no data-handling statement of its own, so it does not say how this panel's samples and data are stored, shared or deleted beyond the general policy.

Reading the labels

What Has Been Checked?

Source collected

Evidence labels stay separate from the Test Grade. They show how much source support exists for the evaluation.

The balance

The Strengths. The Tradeoffs.

Strengths

  • One blood draw screens for signals associated with more than 50 cancer types in total and can provide a conditional Cancer Signal Origin prediction.
  • Positive and no-signal results come with clear screening limitations and diagnostic follow-up guidance.
  • At-home licensed phlebotomy, no fasting and a typical two-to-three-week result window make the collection workflow clear.

Watch-outs

  • Galleri is intended for adults at elevated cancer risk, such as people age 50 and older. It is not recommended during pregnancy, at age 21 or younger, or during active cancer treatment.
  • A detected signal is not a diagnosis and requires diagnostic follow-up. A no-signal result does not rule out cancer. False positives and false negatives are possible; continue routine screening recommended for you.
  • The $949 test fee is separate from annual membership of $349 nationally or $599 in New York and New Jersey. Membership renews annually unless cancelled under its terms. Galleri is non-refundable. Superpower does not publish the cost of diagnostic follow-up after a detected signal.
  • Home collection covers 24 states plus Washington, D.C., with a separate New York and New Jersey version.
  • Cancer-signal performance estimates do not by themselves establish a survival benefit. Results require clinical context.

Take it with you

The Test Truth Card

Keep deciding

Galleri Multi-Cancer Early Detection Test

Mito Health

Useful

Analyzes cell-free DNA methylation patterns for a cancer-associated signal. A detected signal includes a predicted site of origin to guide diagnostic follow-up.

Price
$949
Turnaround
Not confirmed
Labbrary+

Galleri® Multi-Cancer Early Detection Test

Everlywell

Strong

Analyze cell-free DNA methylation patterns for cancer-associated signals using a blood sample collected at Quest. If a signal is detected, the report predicts its likely origin to help guide further evaluation.

Price
$949
Turnaround
28 days
Labbrary+

The Galleri Test

Galleri

Useful

Prescription blood test that looks for cancer-associated DNA methylation signals across more than 50 cancer types. It complements routine screening and predicts an origin when a signal is detected to guide diagnostic follow-up; a negative result does not rule out cancer.

Price
$949
Turnaround
28 days
Labbrary+
Compare

Verification History

October 7, 2026Recorded source date.Source collected

Affiliate disclosure. Some outbound links may earn Labbrary a commission. Affiliate relationships never influence a Test Grade.

LABBRARY / FREE NEWSLETTER

Keep Your
Curiosity Informed.

New tests. Meaningful updates. Smarter questions to ask before you buy. Get Labbrary's free newsletter in your inbox.

Free to join. No account needed. Privacy Policy